You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameTrisalicylate-choline
Accession NumberDB01401
TypeSmall Molecule
GroupsApproved
DescriptionCholine magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28%.(PMID: 1728115, 1618240)
Structure
Thumb
Synonyms
Tricosal
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIINot Available
CAS numberNot Available
WeightAverage: 539.814
Monoisotopic: 539.164188051
Chemical FormulaC26H29MgNO10
InChI KeyInChIKey=FQCQGOZEWWPOKI-UHFFFAOYSA-K
InChI
InChI=1S/3C7H6O3.C5H14NO.Mg/c3*8-6-4-2-1-3-5(6)7(9)10;1-6(2,3)4-5-7;/h3*1-4,8H,(H,9,10);7H,4-5H2,1-3H3;/q;;;+1;+2/p-3
IUPAC Name
magnesium(2+) ion (2-hydroxyethyl)trimethylazanium tris(2-hydroxybenzoate)
SMILES
[Mg++].C[N+](C)(C)CCO.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O.OC1=CC=CC=C1C([O-])=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as salicylic acids. These are ortho-hydroxylated benzoic acids.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassBenzoic acids and derivatives
Direct ParentSalicylic acids
Alternative Parents
Substituents
  • Salicylic acid
  • Benzoic acid
  • Benzoyl
  • Phenol
  • Choline
  • Vinylogous acid
  • Quaternary ammonium salt
  • 1,2-aminoalcohol
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Alkanolamine
  • Hydrocarbon derivative
  • Organic salt
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic zwitterion
  • Aromatic homomonocyclic compound
  • Aliphatic acyclic compound
Molecular FrameworkNot Available
External DescriptorsNot Available
Pharmacology
IndicationCholine magnesium trisalicylate is used to reduce pain and inflammation caused by conditions such as arthritis. This medication is also used to treat fever in adults.
PharmacodynamicsTrisalicylate-choline is a non-steroidal anti-inflammatory drug (NSAID) that contains a combination of choline salicylate and magnesium salicylate. Does not affect platelet aggregation.
Mechanism of actionInhibits prostaglandin synthesis; acts on the hypothalamus heat-regulating center to reduce fever; blocks the generation of pain impulses
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationrenal
Half lifeNot Available
ClearanceNot Available
ToxicitySalicylate intoxication, known as salicylism, may occur with large doses or extended therapy. Common symptoms of salicylism include headache, dizziness, tinnitus, hearing impairment, confusion, drowsiness, sweating, vomiting, diarrhea, and hyperventilation. A more severe degree of salicylate intoxication can lead to CNS disturbances, alteration in electrolyte balance, respiratory and metabolic acidosis, hyperthermia, and dehydration.
Affected organismsNot Available
Pathways
PathwayCategorySMPDB ID
Trisalicylate-choline Action PathwayDrug actionSMP00703
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9852
Blood Brain Barrier-0.8993
Caco-2 permeable+0.5436
P-glycoprotein substrateSubstrate0.7681
P-glycoprotein inhibitor INon-inhibitor0.9522
P-glycoprotein inhibitor IINon-inhibitor0.6479
Renal organic cation transporterNon-inhibitor0.7147
CYP450 2C9 substrateNon-substrate0.7398
CYP450 2D6 substrateNon-substrate0.7764
CYP450 3A4 substrateSubstrate0.588
CYP450 1A2 substrateNon-inhibitor0.7658
CYP450 2C9 inhibitorNon-inhibitor0.8703
CYP450 2D6 inhibitorNon-inhibitor0.7642
CYP450 2C19 inhibitorNon-inhibitor0.8941
CYP450 3A4 inhibitorNon-inhibitor0.9072
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9752
Ames testNon AMES toxic0.7389
CarcinogenicityNon-carcinogens0.729
BiodegradationReady biodegradable0.5807
Rat acute toxicity2.3576 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8568
hERG inhibition (predictor II)Non-inhibitor0.7428
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
Prices
Unit descriptionCostUnit
Choline mag trisal 1 gm tablet1.23USD tablet
Choline mag trisal 750 mg tablet0.81USD tablet
Choline mag trisal 500 mg tablet0.57USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
logP1.98ChemAxon
pKa (Strongest Acidic)2.79ChemAxon
pKa (Strongest Basic)-6.3ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area60.36 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity46.13 m3·mol-1ChemAxon
Polarizability12.38 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabTrisalicylate-choline may increase the anticoagulant activities of Abciximab.
AcebutololTrisalicylate-choline may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Aceclofenac.
AcenocoumarolTrisalicylate-choline may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Trisalicylate-choline.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Trisalicylate-choline.
Alendronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Alendronic acid.
AliskirenTrisalicylate-choline may decrease the antihypertensive activities of Aliskiren.
AlprenololTrisalicylate-choline may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Trisalicylate-choline.
AmikacinTrisalicylate-choline may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideTrisalicylate-choline may decrease the antihypertensive activities of Amiloride.
AncrodTrisalicylate-choline may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Antipyrine.
Antithrombin III humanTrisalicylate-choline may increase the anticoagulant activities of Antithrombin III human.
ApixabanTrisalicylate-choline may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Apremilast.
ArdeparinTrisalicylate-choline may increase the anticoagulant activities of Ardeparin.
ArgatrobanTrisalicylate-choline may increase the anticoagulant activities of Argatroban.
ArotinololTrisalicylate-choline may decrease the antihypertensive activities of Arotinolol.
AtenololTrisalicylate-choline may decrease the antihypertensive activities of Atenolol.
AzapropazoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Trisalicylate-choline.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Trisalicylate-choline.
BalsalazideTrisalicylate-choline may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Trisalicylate-choline.
BecaplerminTrisalicylate-choline may increase the anticoagulant activities of Becaplermin.
BefunololTrisalicylate-choline may decrease the antihypertensive activities of Befunolol.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Trisalicylate-choline.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Trisalicylate-choline.
BenoxaprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Benoxaprofen.
BetaxololTrisalicylate-choline may decrease the antihypertensive activities of Betaxolol.
BevantololTrisalicylate-choline may decrease the antihypertensive activities of Bevantolol.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Trisalicylate-choline.
BisoprololTrisalicylate-choline may decrease the antihypertensive activities of Bisoprolol.
BivalirudinTrisalicylate-choline may increase the anticoagulant activities of Bivalirudin.
BopindololTrisalicylate-choline may decrease the antihypertensive activities of Bopindolol.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Trisalicylate-choline.
BufuralolTrisalicylate-choline may decrease the antihypertensive activities of Bufuralol.
BumetanideTrisalicylate-choline may decrease the diuretic activities of Bumetanide.
BupranololTrisalicylate-choline may decrease the antihypertensive activities of Bupranolol.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Trisalicylate-choline.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Trisalicylate-choline.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Trisalicylate-choline.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Trisalicylate-choline.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Trisalicylate-choline.
CarteololTrisalicylate-choline may decrease the antihypertensive activities of Carteolol.
CarvedilolTrisalicylate-choline may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Trisalicylate-choline.
CeliprololTrisalicylate-choline may decrease the antihypertensive activities of Celiprolol.
CertoparinTrisalicylate-choline may increase the anticoagulant activities of Certoparin.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Trisalicylate-choline.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Trisalicylate-choline.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Trisalicylate-choline.
CholestyramineCholestyramine can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Trisalicylate-choline.
Citric AcidTrisalicylate-choline may increase the anticoagulant activities of Citric Acid.
ClodronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clodronate.
ClonixinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Trisalicylate-choline.
ColesevelamColesevelam can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Trisalicylate-choline resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclosporineTrisalicylate-choline may increase the nephrotoxic activities of Cyclosporine.
D-LimoneneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with D-Limonene.
Dabigatran etexilateTrisalicylate-choline may increase the anticoagulant activities of Dabigatran etexilate.
DalteparinTrisalicylate-choline may increase the anticoagulant activities of Dalteparin.
DanaparoidTrisalicylate-choline may increase the anticoagulant activities of Danaparoid.
DaunorubicinTrisalicylate-choline may decrease the excretion rate of Daunorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DeferasiroxThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Deferasirox.
DesirudinTrisalicylate-choline may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Trisalicylate-choline.
DextranTrisalicylate-choline may increase the anticoagulant activities of Dextran.
Dextran 40Trisalicylate-choline may increase the anticoagulant activities of Dextran 40.
Dextran 70Trisalicylate-choline may increase the anticoagulant activities of Dextran 70.
Dextran 75Trisalicylate-choline may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Trisalicylate-choline.
DicoumarolTrisalicylate-choline may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Trisalicylate-choline.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Trisalicylate-choline.
DihydrostreptomycinTrisalicylate-choline may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Trisalicylate-choline.
DoxorubicinTrisalicylate-choline may decrease the excretion rate of Doxorubicin which could result in a lower serum level and potentially a reduction in efficacy.
DrospirenoneTrisalicylate-choline may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Droxicam.
Edetic AcidTrisalicylate-choline may increase the anticoagulant activities of Edetic Acid.
EdoxabanTrisalicylate-choline may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Trisalicylate-choline.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Trisalicylate-choline.
EnoxaparinTrisalicylate-choline may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Epirizole.
EpirubicinTrisalicylate-choline may decrease the excretion rate of Epirubicin which could result in a lower serum level and potentially a reduction in efficacy.
EplerenoneTrisalicylate-choline may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Trisalicylate-choline.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Trisalicylate-choline.
EsmololTrisalicylate-choline may decrease the antihypertensive activities of Esmolol.
Etacrynic acidTrisalicylate-choline may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Trisalicylate-choline.
Ethyl biscoumacetateTrisalicylate-choline may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Trisalicylate-choline.
EtofenamateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etofenamate.
EtoricoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Etoricoxib.
Evening primrose oilThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Evening primrose oil.
exisulindThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Trisalicylate-choline.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Trisalicylate-choline.
FlunixinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Trisalicylate-choline.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Trisalicylate-choline.
Fondaparinux sodiumTrisalicylate-choline may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Trisalicylate-choline.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Trisalicylate-choline.
FramycetinTrisalicylate-choline may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideTrisalicylate-choline may decrease the diuretic activities of Furosemide.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Trisalicylate-choline.
GentamicinTrisalicylate-choline may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Haloperidol.
HeparinTrisalicylate-choline may increase the anticoagulant activities of Heparin.
HirulogTrisalicylate-choline may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with HMPL-004.
HydralazineTrisalicylate-choline may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Trisalicylate-choline.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Trisalicylate-choline.
Hygromycin BTrisalicylate-choline may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibandronate.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Trisalicylate-choline.
IbuproxamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Icatibant.
IdarubicinTrisalicylate-choline may decrease the excretion rate of Idarubicin which could result in a lower serum level and potentially a reduction in efficacy.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Trisalicylate-choline.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Trisalicylate-choline.
IndenololTrisalicylate-choline may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Trisalicylate-choline.
IndoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Indoprofen.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Trisalicylate-choline.
IsoxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Isoxicam.
KanamycinTrisalicylate-choline may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Trisalicylate-choline.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Trisalicylate-choline.
LabetalolTrisalicylate-choline may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Trisalicylate-choline.
LepirudinTrisalicylate-choline may increase the anticoagulant activities of Lepirudin.
LevobunololTrisalicylate-choline may decrease the antihypertensive activities of Levobunolol.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Trisalicylate-choline.
LithiumThe serum concentration of Lithium can be increased when it is combined with Trisalicylate-choline.
LornoxicamThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Trisalicylate-choline.
LoxoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Trisalicylate-choline.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Trisalicylate-choline.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Trisalicylate-choline.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Trisalicylate-choline.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Trisalicylate-choline.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Trisalicylate-choline.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Trisalicylate-choline.
MesalazineTrisalicylate-choline may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Trisalicylate-choline.
MetamizoleThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Metamizole.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Trisalicylate-choline.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Trisalicylate-choline.
MetipranololTrisalicylate-choline may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Trisalicylate-choline.
MetoprololTrisalicylate-choline may decrease the antihypertensive activities of Metoprolol.
MetrizamideTrisalicylate-choline may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Trisalicylate-choline.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Trisalicylate-choline.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Trisalicylate-choline.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Trisalicylate-choline.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trisalicylate-choline.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Trisalicylate-choline.
NadololTrisalicylate-choline may decrease the antihypertensive activities of Nadolol.
NadroparinTrisalicylate-choline may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Trisalicylate-choline.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Trisalicylate-choline.
NCX 4016The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with NCX 4016.
NeomycinTrisalicylate-choline may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nepafenac.
NetilmicinTrisalicylate-choline may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Niflumic Acid.
NimesulideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Nimesulide.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Trisalicylate-choline.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Trisalicylate-choline.
OlsalazineTrisalicylate-choline may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Trisalicylate-choline.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Trisalicylate-choline.
OrgoteinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Orgotein.
OtamixabanTrisalicylate-choline may increase the anticoagulant activities of Otamixaban.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Trisalicylate-choline.
OxprenololTrisalicylate-choline may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Oxyphenbutazone.
PamidronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Parecoxib.
ParomomycinTrisalicylate-choline may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
PenbutololTrisalicylate-choline may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateTrisalicylate-choline may increase the anticoagulant activities of Pentosan Polysulfate.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Trisalicylate-choline.
PhenindioneTrisalicylate-choline may increase the anticoagulant activities of Phenindione.
PhenprocoumonTrisalicylate-choline may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Trisalicylate-choline.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Trisalicylate-choline.
PindololTrisalicylate-choline may decrease the antihypertensive activities of Pindolol.
PiretanideTrisalicylate-choline may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Trisalicylate-choline.
PlicamycinTrisalicylate-choline may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Trisalicylate-choline.
PractololTrisalicylate-choline may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Trisalicylate-choline.
ProbenecidThe serum concentration of Trisalicylate-choline can be increased when it is combined with Probenecid.
PropacetamolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Propacetamol.
PropranololTrisalicylate-choline may decrease the antihypertensive activities of Propranolol.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Trisalicylate-choline.
Protein CTrisalicylate-choline may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeTrisalicylate-choline may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with PTC299.
PuromycinTrisalicylate-choline may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Trisalicylate-choline.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Trisalicylate-choline.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Trisalicylate-choline.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Trisalicylate-choline.
ResveratrolThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Resveratrol.
ReviparinTrisalicylate-choline may increase the anticoagulant activities of Reviparin.
RibostamycinTrisalicylate-choline may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Risedronate.
RivaroxabanTrisalicylate-choline may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Trisalicylate-choline.
SalicylamideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Trisalicylate-choline.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Trisalicylate-choline.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Trisalicylate-choline.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Trisalicylate-choline.
SeratrodastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Seratrodast.
SotalolTrisalicylate-choline may decrease the antihypertensive activities of Sotalol.
SpectinomycinTrisalicylate-choline may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Trisalicylate-choline.
SpironolactoneTrisalicylate-choline may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with SRT501.
StreptomycinTrisalicylate-choline may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinTrisalicylate-choline may decrease the excretion rate of Streptozocin which could result in a lower serum level and potentially a reduction in efficacy.
SulfasalazineTrisalicylate-choline may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Trisalicylate-choline.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Trisalicylate-choline.
SulodexideTrisalicylate-choline may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Trisalicylate-choline.
TacrolimusTrisalicylate-choline may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Trisalicylate-choline.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Trisalicylate-choline.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Technetium Tc-99m Medronate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Trisalicylate-choline.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Trisalicylate-choline.
TenofovirThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Trisalicylate-choline.
TepoxalinThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Teriflunomide.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiaprofenic acid.
TiludronateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tiludronate.
TimololTrisalicylate-choline may decrease the antihypertensive activities of Timolol.
TobramycinTrisalicylate-choline may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Trisalicylate-choline.
TorasemideTrisalicylate-choline may decrease the diuretic activities of Torasemide.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Trisalicylate-choline.
TranilastThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Tranilast.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Trisalicylate-choline.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Trisalicylate-choline.
TriamtereneTrisalicylate-choline may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Trisalicylate-choline.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Trisalicylate-choline.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Trisalicylate-choline.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Trisalicylate-choline.
WarfarinTrisalicylate-choline may increase the anticoagulant activities of Warfarin.
XimelagatranTrisalicylate-choline may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zaltoprofen.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Trisalicylate-choline.
Zoledronic acidThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Nizankowska E, Dworski R, Soja J, Szczeklik A: Salicylate pre-treatment attenuates intensity of bronchial and nasal symptoms precipitated by aspirin in aspirin-intolerant patients. Clin Exp Allergy. 1990 Nov;20(6):647-52. [PubMed:2083404 ]
  2. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616 ]
  3. Schwartz KA: Aspirin resistance: a review of diagnostic methodology, mechanisms, and clinical utility. Adv Clin Chem. 2006;42:81-110. [PubMed:17131625 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, p...
Gene Name:
PTGS2
Uniprot ID:
P35354
Molecular Weight:
68995.625 Da
References
  1. Simon RA: Adverse respiratory reactions to aspirin and nonsteroidal anti-inflammatory drugs. Curr Allergy Asthma Rep. 2004 Jan;4(1):17-24. [PubMed:14680616 ]
  2. Brzozowski T, Konturek PC, Sliwowski Z, Kwiecien S, Drozdowicz D, Pawlik M, Mach K, Konturek SJ, Pawlik WW: Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals. J Physiol Pharmacol. 2006 Sep;57 Suppl 3:67-79. [PubMed:17033106 ]
  3. Wang HJ, Liu XJ, Yang KX, Luo FM, Lou JY, Peng ZL: [Effects of nonsteroidal anti-inflammatory drug celecoxib on expression of cyclooxygenase-2 (COX-2) in ovarian carcinoma cell]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 Sep;37(5):757-60. [PubMed:17037745 ]
  4. Shen J, Gammon MD, Terry MB, Teitelbaum SL, Neugut AI, Santella RM: Genetic polymorphisms in the cyclooxygenase-2 gene, use of nonsteroidal anti-inflammatory drugs, and breast cancer risk. Breast Cancer Res. 2006;8(6):R71. [PubMed:17181859 ]
  5. Nakano M, Denda N, Matsumoto M, Kawamura M, Kawakubo Y, Hatanaka K, Hiramoto Y, Sato Y, Noshiro M, Harada Y: Interaction between cyclooxygenase (COX)-1- and COX-2-products modulates COX-2 expression in the late phase of acute inflammation. Eur J Pharmacol. 2007 Mar 22;559(2-3):210-8. Epub 2006 Dec 16. [PubMed:17258197 ]
Comments
comments powered by Disqus
Drug created on July 08, 2007 11:07 / Updated on August 17, 2016 12:23